1-ethyl-6-methyl-4-oxo-1,4-dihydro-pyridine-3-carboxylic acid | 70934-34-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 1-ethyl-6-methyl-4-oxo-1,4-dihydro-pyridine-3-carboxylic acid
• 英文别名: 1-Ethyl-6-methyl-4-oxo-1,4-dihydropyridine-3-carboxylic acid；1-ethyl-6-methyl-4-oxopyridine-3-carboxylic acid
• CAS: 70934-34-8
• 化学式: C₉H₁₁NO₃
• 分子量: 181.191
• InChiKey: UOCKZXIOTNFZSN-UHFFFAOYSA-N

物化性质

• 沸点：
  304.7±42.0 °C(Predicted)
• 密度：
  1.237±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  57.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  硫酸二乙酯 、 4-羟基-6-甲基烟酸 在 氢氧化钾 、 四丁基溴化铵 作用下， 反应 3.5h， 以37%的产率得到1-ethyl-6-methyl-4-oxo-1,4-dihydro-pyridine-3-carboxylic acid
  参考文献：
  名称：

  New structure-activity relationships of the quinolone antibacterials using the target enzyme. The development and application of a DNA gyrase assay

  摘要：

  A series of 60 newly synthesized and known quinolone antibacterials, including quinoline- and 1,8-naphthyridine-3-carboxylic acids, pyrido[2,3-d]pyrimidine-6-carboxylic acids, and some monocyclic 4-pyridone-3-carboxylic acids, were tested and compared in a newly established, easy to perform, DNA gyrase assay. The results were correlated with minimum inhibitory concentrations (MICs) against a variety of organisms. Among the known quinolones were 14 clinically significant drugs (oxolinic acid, norfloxacin, ciprofloxacin, enoxacin, etc.) which were used as standards and compared side-by-side. The study focused on the changes in DNA gyrase inhibition brought about by certain features of the molecules, namely, the C6-fluorine or the nature of the C7 substituent. The intrinsic gyrase inhibition of the fused parent rings, quinoline vs. naphthyridine vs. pyrido[2,3-d]pyrimidine, was also explored. In all cases, loss of enzyme inhibition produced poor MICs, but some compounds with good DNA gyrase inhibition did not correspondingly inhibit bacterial growth. Possible explanations for this phenomena and the benefits of a DNA gyrase-MIC strategy for developing future structure-activity relationships are discussed.

  DOI：

  10.1021/jm00153a015

文献信息

• SUBSTITUTED 4-PYRIDONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY
  申请人：OOST Thorsten

  公开号：US20140057920A1

  公开（公告）日：2014-02-27

  This invention relates to substituted 4-pyridones of formula 1 and their use as inhibitors of neutrophil elastase activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of pulmonary, gastrointestinal and genitourinary diseases, inflammatory diseases of the skin and the eye and other auto-immune and allergic disorders, allograft rejection, and oncological diseases.

  本发明涉及公式1的取代4-吡啶酮及其用作中性粒细胞弹性蛋白酶活性抑制剂的药物组合物，以及将其用作治疗和/或预防肺部、胃肠道和泌尿生殖系统疾病、皮肤和眼睛炎症性疾病以及其他自身免疫和过敏性疾病、移植物排斥和肿瘤性疾病的方法。
• [EN] SUBSTITUTED 4-PYRIDONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY<br/>[FR] 4-PYRIDONES SUBSTITUÉES ET LEUR UTILISATION COMME INHIBITEURS DE L'ACTIVITÉ DE L'ÉLASTASE NEUTROPHILE
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2014029832A1

  公开（公告）日：2014-02-27

  P01-2864-ff 32/132 -132- ABSTRACT This invention relates to substituted 4-pyridones of formula R 1a R 7 R 6 R R 3 N O O N H R 4 R 2 R 1b A 1 and their use as inhibitors ofneutrophil elastase activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of pulmonary, gastrointestinal and genitourinary diseases, inflammatory diseases of the skin and the eye and other auto-immune and allergic disorders, allograft rejection, and oncological diseases.

  这项发明涉及化学式为R 1a R 7 R 6 R R 3 N O O N H R 4 R 2 R 1b A 1的取代4-吡啶酮，以及它们作为中性粒细胞弹性蛋白酶活性抑制剂的用途，含有相同化合物的制药组合物，以及将其用作治疗和/或预防肺部、胃肠道和泌尿系统疾病、皮肤和眼睛的炎症性疾病、其他自身免疫和过敏性疾病、移植物排斥反应和肿瘤性疾病的药剂的方法。
• Alpha(pyridonecarboxylamino)-alpha substituted acetamido penicillins and -cephalosporins, process for their preparation, their use in pharmaceuticals; pyridones used in the process
  申请人：SANDOZ AG

  公开号：EP0001041A2

  公开（公告）日：1979-03-21

  α(Pyridonecarbonylamino)-α- substituted acetamido penicillins and -cephalosporins, process for their preparation, their use in pharmaceuticals and pyridones used in the process. The compounds are of formula 1: in which X is The pyridines of formulas IV and VI are also described:

  α(吡啶酮羰基氨基)-α-取代的乙酰氨基青霉素和头孢菌素，其制备工艺，在药物中的用途以及工艺中使用的吡啶酮。 这些化合物如式 1 所示： 其中 X 为 还描述了式 IV 和 VI 的吡啶：
• US9340507B2
  申请人：——

  公开号：US9340507B2

  公开（公告）日：2016-05-17
• US9346794B1
  申请人：——

  公开号：US9346794B1

  公开（公告）日：2016-05-24